These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23744524)

  • 21. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dangerous liaisons: doctors-in-training and the pharmaceutical industry.
    Pokorny AM; Gittins CB
    Intern Med J; 2015 Oct; 45(10):1085-8. PubMed ID: 26429220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Navigating the Murky Waters of Conflict of Interest: Searching for the Middle Path.
    Zonia SC
    J Empir Res Hum Res Ethics; 2016 Feb; 11(1):67-71. PubMed ID: 27106892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical companies' policies on access to trial data, results, and methods: audit study.
    Goldacre B; Lane S; Mahtani KR; Heneghan C; Onakpoya I; Bushfield I; Smeeth L
    BMJ; 2017 Jul; 358():j3334. PubMed ID: 28747301
    [No Abstract]   [Full Text] [Related]  

  • 25. The ethics of pharmaceutical industry gift-giving: the role of a professional association.
    Morin K; Morse LJ
    Am J Bioeth; 2003; 3(3):54-5. PubMed ID: 14594494
    [No Abstract]   [Full Text] [Related]  

  • 26. What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study.
    Parsons S; Starling B; Mullan-Jensen C; Tham SG; Warner K; Wever K
    BMJ Open; 2016 Jan; 6(1):e008928. PubMed ID: 26743701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Building legitimacy by criticising the pharmaceutical industry: a qualitative study among prescribers and local opinion leaders.
    Pittet AL; Saraga M; Stiefel F
    Swiss Med Wkly; 2015; 145():w14240. PubMed ID: 26661626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia.
    Fabbri A; Grundy Q; Mintzes B; Swandari S; Moynihan R; Walkom E; Bero LA
    BMJ Open; 2017 Jun; 7(6):e016701. PubMed ID: 28667226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ethics of expediency.
    Glickel SZ
    J Hand Surg Am; 2009; 34(5):799-807. PubMed ID: 19410982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health educators in the workplace: helping companies respond to the AIDS crisis.
    Bauman LJ; Aberth J
    Health Educ Q; 1986; 13(4):395-406. PubMed ID: 3465714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between European paediatricians and commerce: ethical principles in paediatrics working group recommendations. Confederation of European Societies of Paediatrics (CESP).
    Chambers TL
    Eur J Pediatr; 2000; 159(1-2):116-8. PubMed ID: 10653344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical companies and medical students: a student's view.
    Hutchinson MS
    Med J Aust; 2004 Apr; 180(8):414. PubMed ID: 15089734
    [No Abstract]   [Full Text] [Related]  

  • 34. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ethics of the medical-pharmaceutical relationship.
    Vashi NA; Latkowski JA
    Clin Dermatol; 2012; 30(2):188-91. PubMed ID: 22330662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combating corruption in the pharmaceutical arena.
    Lexchin J; Kohler JC; Gagnon MA; Crombie J; Thacker P; Shnier A
    Indian J Med Ethics; 2018; 3(3):234-239. PubMed ID: 29550750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trust: need for an improved communication between the public world and the pharmaceutical companies.
    Heinemann L
    J Diabetes Sci Technol; 2009 Jan; 3(1):210-2. PubMed ID: 20046667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific misconduct, the pharmaceutical industry, and the tragedy of institutions.
    Cohen-Kohler JC; Esmail LC
    Med Law; 2007 Sep; 26(3):431-46. PubMed ID: 17970244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethics, profit and patients: when pharmaceutical companies sponsor medical meetings.
    Barton L
    J Hosp Mark; 1993; 8(1):71-82. PubMed ID: 10135504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Patents in pharmaceutical industry: between ethics and property rights].
    Martínez Cárdenas EE
    Rev Salud Publica (Bogota); 2003; 5(1):18-23. PubMed ID: 14658364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.